Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Disease area: Airway diseases

Abstract

Purpose of the study. To study the values of FENO in respiratory diseases and the relationship with disease stage and pulmonary function tests.
Materials and Methods.This was a prospective study. FeNO has been measured in 111 patients: 41 with asthma, 3 GERD, 19 bronchiectasis, 11 sarcoidosis, 23 COPD, 14 secondary Pulmonary Hypertension. FeNO was measured by chemoluminescence using NIOX MINO, consistent with the ATS guidelines published in 2005.
We used t test and ANOVA. Significance was defined as a p value of < 0.05.
Results. The mean of FENO in asthma was 30.5pp ±30.7SD with range 5 – 124. p=0.003. The mean of FENO was 91ppb in moderate stage, 80.5ppb in inttermitent, 63ppb in severe and 60ppb in mild stage.The mean of FENO in the asthma with normal value of IgE and high value of IgE were 15.8 ±13.4SD and 64.9 ±28.1SD respectively. P<0.01.The mean of FENO in the diseases with obstruction of the small airway was 18.2±20.4SD with range 5 – 63.The mean of FENO in GERD with obstruction of the small airway was 6.7 ±2.1SD, the mean of FENO in asthma with obstruction of the small airway was 27.0 ±25.0SD.p=0.2. (the difference is very high but it has not brought significant change due to the small size of the sample). The mean of FENO in COPD was higher in the second stage (41) than the third stage (13.5) and the fourth stage (7.7) The mean FENO in secondary pulmonary hypertension was 12.2 ±5.6D with range 5 – 20.
Conclusions. The value of FeNO in asthma is not correlated with the values of FEV1 but with the activity of eosinophilic inflammation and atopy. There was significant change between the mean of FENO to the stages of COPD. There was negative moderate correlation between the value of FENO and PSAP.

Rating:

Share or cite this content

Citations should be made in the following way:
E. Dilka, A. Cuko, D. Argjiri, R. Kore, J. Beli, E. Shehu, E. Tashi, E. Ndreu, E. Nushi, A. Tanku, A. Simaku, P. Kapisyzi (Tirana, Albania). Exhaled nitric oxide in diagnosis and management of respiratory diseases. Eur Respir J 2013; 42: Suppl. 57, 4159

Member's Comments

No comment yet.

Related content which might interest you: Characterization of airway inflammation in patients with asthma COPD overlap syndrome using FeNO levels Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 The role of FeNO measurement in exploration of respiratory symptoms in children with no diagnosis of asthma Source: International Congress 2015 – Paediatric epidemiology: pulmonary complications, bronchiolitis and asthma Year: 2015 Exhaled nitric oxide in respiratory diseases other than asthma Source: Eur Respir Monogr 2010; 49: 45-55 Year: 2010 Role of fractional exhaled nitric oxide(FeNO) in obstructive airway diseases in Indian population Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Temporal stability of feno measurement in COPD Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Characterization of allergic airway inflammation in patients with COPD using fractional exhaled nitric oxide levels Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013 Fractional exhaled nitric oxide in chronic obstructive pulmonary disease Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Exhaled nitric oxide in childhood asthma Source: Annual Congress 2006 - Paediatric Respiratory Research Award Year: 2006 Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD Source: Eur Respir J 2010; 35: 72-78 Year: 2010 Combination of elevated exhaled nitric oxide and serum eosinophil cationic protein identifies asthma patients at risk for exacerbation Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015 Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma Source: Eur Respir J 2008; 32: 344-349 Year: 2008 Further evidence that FeNO directed therapy reduces asthma exacerbations Source: International Congress 2014 – Airway biomarkers Year: 2014 Meta-analysis of the accuracy of screening adult asthma using exhaled nitric oxide Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Exhaled nitric oxide and the therapeutic regimens in childhood asthma Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013 The experience of monitoring the exhaled nitric oxide (FeNO) during the anti-IgE-therapy (omalizumab) in children with uncontrolled severe asthma Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Differences in exhaled nitric oxide levels between patients with cystic fibrosis and atopic bronchial asthma Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Small airway dysfunction and its role in pediatric asthma control assessment Source: International Congress 2016 – Techniques and tools in paediatric asthma Year: 2016 Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma Source: Eur Respir J 2006; 27: 951-956 Year: 2006 Exhaled NO (FENO50) in COPD - Results from the TIE-study Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Exhaled nitric oxide as the sole determinant of therapy in all obstructive patients in a primary care setting: long-lasting effects on health related quality of life Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care Year: 2007